Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (10) , 2924-2938
Abstract
Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent 111In-DTPA-D2B-IRDye700DX was developed and characterized for both pre- and intra-operative tumor localization and eradication of (residual) tumor tissue by PSMA-targeted photodynamic therapy (tPDT), which is a highly selective cancer treatment based on targeting molecules conjugated to photosensitizers that can induce cell destruction upon exposure to near-infrared (NIR) light.Keywords
This publication has 35 references indexed in Scilit:
- Radiofluorinated Derivatives of 2-(Phosphonomethyl)pentanedioic Acid as Inhibitors of Prostate Specific Membrane Antigen (PSMA) for the Imaging of Prostate CancerJournal of Medicinal Chemistry, 2012
- Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive CoresEuropean Urology, 2012
- Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of ImmunoconjugateBioconjugate Chemistry, 2012
- Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian CancerJournal of Nuclear Medicine, 2011
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancerThe Prostate, 2009
- Prognostic Significance of Location of Positive Margins in Radical Prostatectomy SpecimensUrology, 2007
- Variations Among Individual Surgeons in the Rate of Positive Surgical Margins in Radical Prostatectomy SpecimensJournal of Urology, 2003
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995